BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20030680)

  • 1. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
    Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
    Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Habuchi T; Suzuki T
    Steroids; 2008 Oct; 73(11):1052-9. PubMed ID: 18502461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.
    Hamzah S; Teh LK; Siew JS; Ahmad G; Wong HS; Zakaria ZA; Salleh MZ
    Can J Physiol Pharmacol; 2014 Jan; 92(1):50-7. PubMed ID: 24383873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
    Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
    Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
    Woodahl EL; Hingorani SR; Wang J; Guthrie KA; McDonald GB; Batchelder A; Li M; Schoch HG; McCune JS
    Pharmacogenomics J; 2008 Aug; 8(4):248-55. PubMed ID: 17700595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
    J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
    Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
    Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
    J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
    García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.
    Onizuka M; Kunii N; Toyosaki M; Machida S; Ohgiya D; Ogawa Y; Kawada H; Inoko H; Ando K
    Bone Marrow Transplant; 2011 Aug; 46(8):1113-7. PubMed ID: 21102498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
    Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
    Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
    Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
    Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.